A Phase 2 interventional study of RRx-001 and Cisplatin for injection in Oral Mucositis, sponsored by EpicentRx, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-04.
Sponsored by EpicentRx, Inc. · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Stomatitis with a site in United States — 12 open to participants now, 15 under way, none of them phase 3. Stomatitis · United States.
Among the 80 studies in Stomatitis with a site in United States, this one is the 40th largest by enrollment of the 73 interventional ones that give a count, is one of 8 that started in 2018, is one of 33 in phase 2, and was the 55th registered.
307 studies on the registry are indexed under Stomatitis; 74 are open to participants now.
Browse Stomatitis studies →12 of the 80 studies in Stomatitis with a site in United States are open now. Recruiting first, the newest first:
UNCANCER LLC · Sites in United States
Ages 18+
Baptist Health South Florida · Sites in United States
Ages 18+
AstraZeneca · Sites in United States
Ages 18+
Woman's · Sites in United States
Ages 18+
NRG Oncology · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Stomatitis studies recruiting now, 20 (44%) set no upper age limit and 21 (47%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 35 · Phase 3 9 · Phase 4 4
First in 1999; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 60 across 277 interventional studies indexed under Stomatitis.
Median enrollment 60 across the 73 interventional studies, 22 across the 6 observational. Of the 60 that completed or were terminated, 26 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 80 have an industry lead sponsor. The 10 most frequent:
EpicentRx, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
EpicentRx, Inc. has 2 studies filed under Stomatitis — fewer than ten, so there is no comparison to draw.
8 of the studies in Stomatitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07290413Brigham and Women's HospitalPhotobiomodulation for the Prevention of Oral Mucositis | 2026-12 |
| NCT04805320University of NebraskaAssociation of Periodontal Inflammation on Immune Response in Wound Healing | 2027-01 |
| NCT06532279NRG OncologyTesting the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | 2027-01-01 |
| NCT07287826Woman'sUsing a Steroid Mouthwash to Prevent Mouth Sores During Chemotherapy | 2027-07 |
| NCT05966194EpicentRx, Inc.RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer | 2027-07-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 80 studies in Stomatitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the duration or length of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients in arms 1, 2 and 3 will also receive RRx-001 on different schedules.
The standard treatment for head and neck cancer currently includes a chemotherapy drug called cisplatin that is given by intravenous (IV) infusion and radiation, which is delivered from a machine that precisely targets the tumor. One common and unfortunate side effect of treatment with cisplatin and radiation is oral mucositis, which refers to irritation of the lining of the mouth. Oral mucositis is a serious problem 1) because the open mouth sores from oral mucositis may lead to severe pain, nutritional problems and dehydration from an inability to eat and drink, an increased risk of infection from bacteria and fungus and delay or discontinuation of treatment and 2) because there is only one approved therapy to treat or prevent it.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have adequate organ and marrow function as defined below:
A. (ANC) >1,500 / mm3 B. > 100,000 / mm3 C. ≥ 9.0 g/dL
Adequate renal and liver function as indicated by:
A. Serum creatinine acceptable for treatment with cisplatin per institutional guidelines) B. Total ≤ 1.5 x upper-normal limit () C. (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN D. Alkaline phosphatase ≤ 2.5 x ULN
Women of and men with partners of child-bearing potential must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.
Note: A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC (four doses total). No additional RRx-001 will be given during the course of RT/cisplatin
Drug: RRx-001 · Drug: Cisplatin for injection · Radiation: Radiation Therapy
Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day in each of weeks 2 and 5 during RT/cisplatin administration
Drug: RRx-001 · Drug: Cisplatin for injection · Radiation: Radiation Therapy
Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day of each of the first 6 weeks during RT/cisplatin administration
Drug: RRx-001 · Drug: Cisplatin for injection · Radiation: Radiation Therapy
No doses of RRx-001 will be administered. Patients assigned to this arm will receive only standard of care in the form of a 7-week course of fractionated radiation therapy concurrent with a high-dose cisplatin regimen (100 mg/m2 dose in each of RT weeks 1, 4, and 7).
Drug: Cisplatin for injection · Radiation: Radiation Therapy
RRx-001 for injection
Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients
Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study
Duration of Severe Oral Mucositis (SOM)
Duration in days of severe oral mucositis (SOM). Defined as oral mucositis grade 3 or 4 on the WHO Mucositis Grading Scale which comprises 5 grades: 0 = none, 1= oral soreness, erythema, 2 = oral erythema, ulcers, solid diet tolerated, 3 = oral ulcers, liquid diet only, and 4 = oral alimentation impossible. Severe Oral Mucositis duration is obtained by totaling the number of days a given patient experiences oral mucositis grade 3 or 4 during the randomized treatment period. Higher Severe Oral Mucositis duration numbers are indicative of worst outcomes. The total Severe Oral Mucositis duration for a given patient will range between 0 days and the maximum number of days the patient participated in the randomized treatment period.
Time frame: From start of treatment through 28 days post treatment for up to 11 weeks from Start of Treatment
Time to Onset of Severe Oral Mucositis
Time to onset of Severe Oral Mucositis defined as time (in days) from randomization to the first observed Severe Oral Mucositis. Longer Severe Oral Mucositis onset times are indicative of a better outcome. The time to onset of Severe Oral Mucositis for a given patient will range between 0 days and the maximum number of days the patient participated in the randomized treatment period.
Time frame: Time from Day 1 to Oral Mucositis Onset (up to 8 weeks)
Incidence of Severe Oral Mucositis
Incidence of Severe Oral Mucositis defined as the number of patients who experienced a Severe Oral Mucositis grade 4 during the randomized treatment period.
Time frame: Baseline through end of treatment (up to 11 weeks). Data collected every week.
Opioid Use
Opioid use from the time to onset (TTO) and duration of opioid use among patients who were not taking opioids at radiation start or who required a second opioid during active treatment.
Time frame: Baseline through end of radiation treatment (through 8 weeks). Data collected every week.
| Milestone | RRx-001 Pre-Treatment Plus SOC | RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC | RRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOC | Standard of Care |
|---|---|---|---|---|
| Started | 14 | 13 | 13 | 13 |
| Completed | 9 | 10 | 9 | 8 |
| Not completed | 5 | 3 | 4 | 5 |
| Withdrew: Lack of efficacy | 2 | 0 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Screen failure (baseline dropout) | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 1 | 3 |
| Withdrew: Physician decision | 1 | 0 | 0 | 1 |
Duration in days of severe oral mucositis (SOM). Defined as oral mucositis grade 3 or 4 on the WHO Mucositis Grading Scale which comprises 5 grades: 0 = none, 1= oral soreness, erythema, 2 = oral erythema, ulcers, solid diet tolerated, 3 = oral ulcers, liquid diet only, and 4 = oral alimentation impossible. Severe Oral Mucositis duration is obtained by totaling the number of days a given patient experiences oral mucositis grade 3 or 4 during the randomized treatment period. Higher Severe Oral Mucositis duration numbers are indicative of worst outcomes. The total Severe Oral Mucositis duration for a given patient will range between 0 days and the maximum number of days the patient participated in the randomized treatment period.
| Days | RRx-001 Pre-Treatment Plus SOC | RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC | RRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOC | Standard of Care |
|---|---|---|---|---|
| Duration of Severe Oral Mucositis (SOM) | 22.9 ± 19.08 | 27.7 ± 23.72 | 35.2 ± 28.83 | 37.8 ± 29.33 |
Time to onset of Severe Oral Mucositis defined as time (in days) from randomization to the first observed Severe Oral Mucositis. Longer Severe Oral Mucositis onset times are indicative of a better outcome. The time to onset of Severe Oral Mucositis for a given patient will range between 0 days and the maximum number of days the patient participated in the randomized treatment period.
| Days to Onset | RRx-001 Pre-Treatment Plus SOC | RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC | RRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOC | Standard of Care |
|---|---|---|---|---|
| Time to Onset of Severe Oral Mucositis | 38 (26 to NA) | 33 (22 to NA) | 37 (22 to NA) | 26 (18 to NA) |
Incidence of Severe Oral Mucositis defined as the number of patients who experienced a Severe Oral Mucositis grade 4 during the randomized treatment period.
| Participants | RRx-001 Pre-Treatment Plus SOC | RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC | RRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOC | Standard of Care |
|---|---|---|---|---|
| Incidence of Severe Oral Mucositis | 0 | 4 | 6 | 3 |
Opioid use from the time to onset (TTO) and duration of opioid use among patients who were not taking opioids at radiation start or who required a second opioid during active treatment.
| Participants | RRx-001 Pre-Treatment Plus SOC | RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC | RRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOC | Standard of Care |
|---|---|---|---|---|
| Week 1 | 1 | 0 | 0 | 1 |
| Week 2 | 2 | 0 | 1 | 2 |
| Week 3 | 4 | 2 | 2 | 4 |
| Week 4 | 4 | 2 | 2 | 4 |
| Week 5 | 4 | 2 | 3 | 4 |
| Week 6 | 4 | 2 | 3 | 4 |
| Week 7 | 4 | 2 | 3 | 4 |
| Week 8 | 4 | 2 | 4 | 5 |
Collected over Adverse Events were collected beginning at baseline through end of treatment (12 weeks). All-Cause Mortality was assessed up to 12 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RRx-001 Pre-Treatment Plus SOC | 0/12 (0%) | 4/12 (33.3%) | 9/12 (75%) |
| RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC | 0/11 (0%) | 4/11 (36.4%) | 10/11 (90.9%) |
| RRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOC | 1/13 (7.7%) | 6/13 (46.2%) | 12/13 (92.3%) |
| Standard of Care | 0/10 (0%) | 5/10 (50%) | 6/10 (60%) |
| Event | RRx-001 Pre-Treatment Plus SOC | RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC | RRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOC | Standard of Care |
|---|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 0/12 | 3/11 | 0/13 | 0/10 |
| Atrial fibrillationCardiac disorders | 0/12 | 0/11 | 0/13 | 1/10 |
| NauseaGastrointestinal disorders | 1/12 | 1/11 | 0/13 | 1/10 |
| VomitingGastrointestinal disorders | 1/12 | 0/11 | 0/13 | 1/10 |
| Lung infectionInfections and infestations | 0/12 | 0/11 | 0/13 | 1/10 |
| HypophosphataemiaMetabolism and nutrition disorders | 0/12 | 0/11 | 0/13 | 1/10 |
| ColitisGastrointestinal disorders | 0/12 | 1/11 | 0/13 | 0/10 |
| StomatitisGastrointestinal disorders | 0/12 | 1/11 | 1/13 | 0/10 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/12 | 0/11 | 0/13 | 0/10 |
| Atrial flutterCardiac disorders | 1/12 | 0/11 | 0/13 | 0/10 |
| Event | RRx-001 Pre-Treatment Plus SOC | RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC | RRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOC | Standard of Care |
|---|---|---|---|---|
| Lymphocyte count decreasedInvestigations | 2/12 | 5/11 | 4/13 | 3/10 |
| DysphagiaGastrointestinal disorders | 0/12 | 1/11 | 4/13 | 4/10 |
| White blood cell count decreasedInvestigations | 2/12 | 4/11 | 2/13 | 1/10 |
| Neutrophil count decreasedInvestigations | 1/12 | 3/11 | 4/13 | 0/10 |
| NauseaGastrointestinal disorders | 1/12 | 1/11 | 1/13 | 2/10 |
| Oral dysesthesiaGastrointestinal disorders | 0/12 | 0/11 | 1/13 | 2/10 |
| VomitingGastrointestinal disorders | 1/12 | 0/11 | 1/13 | 2/10 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/12 | 1/11 | 1/13 | 2/10 |
| HypertensionVascular disorders | 1/12 | 0/11 | 0/13 | 2/10 |
| Acute kidney injuryRenal and urinary disorders | 0/12 | 2/11 | 0/13 | 0/10 |
Safety Population comprises all subjects who are randomized and received at least 1 dose of study drug and will be used for all analyses of safety. Analysis is based on actual treatment group
| Age, Continuous(years) | RRx-001 Pre-Treatment Plus SOC | RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC | RRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOC | Standard of Care | Total |
|---|---|---|---|---|---|
| Mean | 57.7 ± 11.17 | 56.7 ± 7.64 | 59 ± 11.94 | 59.5 ± 6.0 | 58.2 ± 9.48 |
| Sex: Female, Male(Participants) | RRx-001 Pre-Treatment Plus SOC | RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC | RRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOC | Standard of Care | Total |
|---|---|---|---|---|---|
| Female | 2 | 2 | 1 | 1 | 6 |
| Male | 10 | 9 | 12 | 9 | 40 |
| Ethnicity (NIH/OMB)(Participants) | RRx-001 Pre-Treatment Plus SOC | RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC | RRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOC | Standard of Care | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 | 2 |
| Not Hispanic or Latino | 11 | 10 | 13 | 9 | 43 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | RRx-001 Pre-Treatment Plus SOC | RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC | RRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOC | Standard of Care | Total |
|---|---|---|---|---|---|
| Asian | 0 | 0 | 1 | 1 | 2 |
| Black or African American | 1 | 1 | 0 | 1 | 3 |
| White | 11 | 10 | 12 | 8 | 41 |
| Region of Enrollment(participants) | RRx-001 Pre-Treatment Plus SOC | RRx-001 Pre-Treatment, 2 Concurrent Doses Plus SOC | RRx-001 Pre-Treatment, 6 Concurrent Doses Plus SOC | Standard of Care | Total |
|---|---|---|---|---|---|
| United States | 12 | 11 | 13 | 10 | 46 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2018 to primary completion in Oct 2019, 15 months.
Results were first posted in Nov 2024, 5 years after primary completion.
Of 39 phase 2 interventional studies under Stomatitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: RRx-001
EpicentRx, Inc.